{
    "clinical_study": {
        "@rank": "9830", 
        "acronym": "TIGER", 
        "arm_group": {
            "arm_group_label": "Tigecycline (Tygacil)", 
            "description": "Subjects who are treated with tigecycline"
        }, 
        "brief_summary": {
            "textblock": "To collect retrospectively the effectiveness and safety information of tigecycline related\n      to their appropriate use in daily practice."
        }, 
        "brief_title": "Tygacil Drug Use Investigation", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Intra-Abdominal Infections", 
            "Skin Disease, Infectious"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection", 
                "Skin Diseases", 
                "Skin Diseases, Infectious"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients who are prescribed tigecycline (Tygacil).\n\n        Exclusion Criteria:\n\n          -  Subject who have been prescribed tigecycline (Tygacil)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The patients whom an investigator involving B1811187 prescribes the tigecycline (Tygacil)."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789905", 
            "org_study_id": "B1811187"
        }, 
        "intervention": {
            "arm_group_label": "Tigecycline (Tygacil)", 
            "description": "Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.", 
            "intervention_name": "Tigecycline (Tygacil)", 
            "intervention_type": "Drug", 
            "other_name": "Tygacil, Tigecycline"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tigecycline", 
                "Minocycline"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Tygacil", 
            "Tigecycline", 
            "Post marketing surveillance", 
            "Japanese", 
            "Infection"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1811187&StudyName=Tygacil%20Drug%20Use%20Investigation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-Drug Resistance.)", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clinical response was assigned by the investigator. A clinical response of cure was defined as: Test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. Test-of-cure performed 10-28 days after last dose of study drug.", 
            "measure": "Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789905"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}